Gate Neurosciences

Venture capital investment dropped about 41% for biopharma firms for the third quarter from Q2, with 94 companies raising $4.5bn in Q3, down from 251 companies that raised $7.6bn in Q2, according to t

Theravance Biopharma Inc. will eliminate debt from its balance sheet and improve its cash balance through the sale of its interest in Theravance Respiratory Company LLC (TRC) – representing an 85% sh